LEIDEN, Netherlands, March 12, 2023 /PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company")( Euronext Amsterdam: PHARM) (Nasdaq: PHAR) is aware that the Federal Deposit Insurance Corporation
/PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) presents its preliminary, unaudited financial.
/PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) confirms it will announce financial results for.
/PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that the US Food and Drug Administration.
The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary